Cargando…
PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer
In addition to the FDA-approved definition of a circulating tumor cell (CTC), various CTC phenotypes have been discovered. Epithelial-mesenchymal transition (EMT) of cancer cells is directly linked to PD-L1 upregulation. The goal of the study was to investigate PD-L1 expression and EMT in CTCs of no...
Autores principales: | Manjunath, Yariswamy, Upparahalli, Sathisha V., Avella, Diego M., Deroche, Chelsea B., Kimchi, Eric T., Staveley-O’Carroll, Kevin F., Smith, Charles J., Li, Guangfu, Kaifi, Jussuf T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628040/ https://www.ncbi.nlm.nih.gov/pubmed/31212653 http://dx.doi.org/10.3390/cancers11060806 |
Ejemplares similares
-
(18)F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer
por: Avella, Diego M., et al.
Publicado: (2020) -
Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018) -
Tumor-Cell–Macrophage Fusion Cells as Liquid Biomarkers and Tumor Enhancers in Cancer
por: Manjunath, Yariswamy, et al.
Publicado: (2020) -
Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses
por: Suvilesh, Kanve N., et al.
Publicado: (2022) -
Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice
por: Li, Guangfu, et al.
Publicado: (2018)